Measuring shared decision making in oncology: Development and first testing of the iSHAREpatient and iSHAREphysician questionnaires

Hanna Bomhof-Roordink1 | Fania R. Gärtner1 | Nanny van Duijn-Bakker1 | Trudy van der Weijden2 | Anne M. Stiggelbout1 | Arwen H. Pieterse1

Abstract

Background: Existing measures to assess shared decision making (SDM) have often been developed based on an ill-defined underlying construct, and many assess physician behaviours only or focus on a single patient-physician encounter.

Objective: To (a) develop a patient and a physician questionnaire to measure SDM in oncology and (b) determine their content validity and comprehensibility.

Methods: A systematic review of SDM models and an oncology-specific SDM model informed the domains of the SDM construct. We formulated items for each SDM domain. Cancer patients and physicians rated content validity in an online questionnaire. We assumed a formative measurement model and performed online field-testing in cancer patients to inform further item reduction. We tested item comprehension in cognitive interviews with cancer patients and physicians.

Results: We identified 17 domains and formulated 132 items. Twelve cancer patients rated content validity at item level, and 11 physicians rated content validity at domain level. We field-tested the items among 131 cancer patients and conducted cognitive interviews with eight patients and five physicians. These phases resulted in the 15-item iSHAREpatient and 15-item iSHAREphysician questionnaires, covering 13 domains.

Conclusions: We thoroughly developed the iSHARE questionnaires. They both assess patient and physician behaviours and cover the entire SDM process rather than a single consultation.

Keywords
content validity, field-testing, formative, oncology, questionnaire, shared decision making
1 | BACKGROUND

Developing a measurement instrument is not something to be done on a rainy Sunday afternoon. If it is done properly, it may take years.

d’e Vet et al – ‘Measurement in Medicine’

Shared decision making (SDM) between patient and physician is considered the pinnacle of patient-centred care. As a consequence, there is an urge to establish existing SDM levels and to detect the effect of SDM training and interventions. Measurement instruments to assess the SDM process exist but have demonstrated several issues relating to what they intend to assess and how they have been developed. Recent systematic reviews of SDM measurement instruments concluded that developers often do not or only vaguely define the underlying construct, and that available SDM measurement instruments substantially differ in the domains that they cover. Patient behaviour is part of SDM models, but often-used SDM measurement instruments only assess physician behaviour (e.g. OPTION, CollaboRATE) or include physician behaviour when assessing patient’s weighing of treatment options (e.g. SDM-Q-9, SDM-Q-Doc), impeding a transparent assessment of patient’s role. The scope of SDM assessments is usually limited to a single consultation, while SDM extends to time outside consultations and is not confined to the space where the patient and physician meet. There is growing awareness of the need for a valid measurement instrument that is capable of capturing the entire SDM process. Such a measurement instrument should be based on a clearly defined construct and include both patient and physician behaviours, during as well as outside consultations.

Existing SDM measurement instruments vary in terms of the viewpoint from which SDM is reported. This can either be that of an independent observer (e.g. OPTION-S), the patient (e.g. SDM-Q-9, CollaboRATE), the physician (e.g. SDM-Q-Doc) or a combination thereof (e.g. MAPPIN/SDM). Overall, agreement between the different viewpoints has been found to be poor. Recently again, a poor agreement (r = .14) between the SDM-Q-9 and SDM-Q-doc was found in an oncology setting. Possibly, discrepancies occur because patients and physicians have different perspectives on what SDM entails and because they seldom have been involved in the development of SDM measurement instruments to date. Moreover, guidelines on the evaluation of psychometric properties of health measurement instruments recommend that the target group (i.e. researchers, patients and/or physicians) should be involved in content validity testing, next to conducting cognitive interviews. This has occurred for only six of the 40 existing SDM measurement instruments.

We set out to develop a questionnaire based on an explicit underlying construct, and observing further recommendations on the development of measurement instruments. We considered a questionnaire most appropriate to develop as recording and coding consultations is a time-consuming process. Further, we posit that for the assessment of SDM a formative measurement model should be assumed. That is, we view the SDM process as a composite construct that is the result of independent indicators (i.e. the items form the construct), which can, but need not, be correlated with each other. In contrast, the developers of most available SDM measurement instruments have assumed a reflective measurement model, in which the latent SDM construct is responsible for the scores on the indicators (i.e. the items reflect the construct).

We decided to develop an SDM questionnaire for the oncology setting because cancer patients often face preference-sensitive decisions that call for SDM. Cancer patients likely feel highly vulnerable, and decisions need to be made about treatment options that often have severe and irreversible side-effects. At the same time, high levels of uncertainty may exist, and time is often a constraint. We further preferred an oncology-specific questionnaire, as definitions of SDM differ between health-care settings.

Therefore, the present study aimed to (a) develop a patient and a physician questionnaire to measure SDM in oncology and (b) determine their content validity and comprehensibility.

2 | METHODS

2.1 | Study design

We aimed to develop short questionnaires to measure SDM from the patient and the physician viewpoint, with the same items formulated from the two different perspectives. We even preferred the physician questionnaire to contain a smaller number of items, all part of the patient questionnaire.

We used the COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist as a guideline throughout the development process. We describe the different phases in more detail in the sections below and in Figure 1. In sum, we selected domains to define the SDM construct; created an item pool to assess the domains; tested content validity (i.e. relevance and comprehensiveness) of the item pool in cancer patients and of the domains in physicians and performed a field-test to further inform the selection of domains and items; and determined comprehensibility of the draft versions of the questionnaires in in-person cognitive interviews. Note that the selection of items was informed by the results obtained by field-testing and not based on internal consistency testing and factor analysis, since we assumed a formative measurement model. Further, throughout the development process our goal was to assess domains that were essential for SDM in oncology, in order to be specific rather than comprehensive. We adopted this approach so that we would include domains that were unique to SDM and would assess shared decision making rather than other decision-making models. Also, we focused on observable behaviour, assuming that this will contribute to achieving more agreement between patients’ and physicians’ viewpoints when assessing SDM. We performed
FIGURE 1  Visual representation of the development process of the iSHARE questionnaires
a side-study to determine the most appropriate and feasible response scale for the questionnaires and tested several formats during the cognitive interviews (see Section 2.7), to select the final response scale.  

2.2 | Participant recruitment

For content validity testing in patients, we approached cancer patients aged ≥18 years and able to speak and write Dutch, via their physician at the LUMC, through either a letter or during a consultation. Patients willing to participate sent their written informed consent to the researcher and then received the link to the online survey. For field-testing, we approached cancer patients participating in an online panel (Kanker.nl), who had agreed to be approached for research, by e-mail and sent them the link to the online survey. They provided informed consent by checking a box at the start of the survey. For the cognitive interviews, we approached cancer patients as described for content validity testing and scheduled an interview at the LUMC. They received reimbursement for travel expenses. We asked for patients’ age and education. The patients further reported their diagnosis (field-testing) or it was obtained from their treating physician (content validity testing and cognitive interviews).

For content validity testing in physicians, we approached physicians treating cancer patients from one Dutch academic hospital (LUMC) and from two Dutch non-academic hospitals (Haga Hospital, The Hague, and Reinier de Graaf, Delft) by e-mail and sent them the link to the online survey. For the cognitive interviews, we approached physicians from the LUMC by e-mail and if they agreed to participate, we scheduled an interview at their workplace.

2.3 | Construct definition and item pool creation

To determine the SDM construct, we made a first selection of domains based on (a) an SDM model in oncology informed by the views of cancer patients, health-care professionals and SDM researchers, and (b) the first search (up to June 21, 2016) for a systematic review of SDM models across settings.

Next, we shared the list of domains with international SDM experts and discussed it first by e-mail and then in person at the 2017 International Shared Decision Making Conference in Lyon, France. The research team made a definitive selection of domains forming the SDM construct.

Finally, we created an item pool for the patient questionnaire by formulating five or more potential items per domain. If available, we used phrasings that patients had used in an earlier interview study and included relevant items from the SDM-Q-9. We asked the international SDM experts for feedback on how well the proposed items reflected the domains, and the research team made a definitive selection of items to present to patients during content validity testing.

2.4 | Content validity testing in patients

First, we pilot-tested questions asking to rate the importance of each item for the domain to which it belonged among two research assistants from outside the research team. As they both considered almost all items to be very important, we decided it to be more informative to ask patients to select the most important items for each domain. Specifically, we presented the patients with the name and description of each domain of SDM in oncology together with the proposed items and asked them to choose the three items that they considered most important for each domain. We further asked them to indicate per domain if the proposed items comprehensively represented it. We then presented the complete list of domains, without items, and asked the patients to indicate if they missed one or more domains, or considered one or more domains to be redundant. In the final step, we asked the patients to judge the clarity (yes/no) of the draft introduction of the iSHAREpatient questionnaire.

We aimed to narrow down the total number of selected items to approximately 50. Two researchers (NDB and HBR) independently selected the items to be used for assessing content validity in physicians and field-testing in patients based on the results, discussed their selection and reached agreement in consultation with the research team.

2.5 | Content validity testing in physicians

We asked physicians to rate the importance of each domain for SDM in oncology, described as ‘doctors and patients making decisions together about cancer treatment’, on a seven-point scale ranging from ‘not important at all’ to ‘very important’. Next, we presented the complete list of domains and asked the physicians to indicate if they missed one or more domains or considered one or more domains to be redundant. We then asked which three domains describing patient behaviour and which six domains describing physician behaviour they considered most important for SDM in oncology. These numbers differed because the construct included more domains describing physician than patient behaviour. Finally, in order to create a physician questionnaire that would be as short as possible, we asked which four to six domains of the complete list they considered indispensable in order to assess SDM with a physician questionnaire.

2.6 | Field-testing in patients

We asked patients to rate the importance of each item for each domain, on a seven-point scale ranging from ‘not important at all’ to ‘very important’; to choose the most important item for each domain; and to indicate for each domain if they missed one or more items. We then presented the complete list of domains, without items, and asked the patients to indicate if they missed one or more domains or considered one or more domains to be redundant. We finally asked which three domains describing patient behaviour and
which six domains describing physician behaviour they considered most important for SDM in oncology.

We selected domains for the draft patient questionnaire informed by the results from the field-testing in patients and the content validity testing in physicians. We selected items for the draft patient questionnaire informed by the results from the field-testing in patients. We selected domains for the draft physician questionnaire informed by the four to six domains chosen by physicians in the final step of content validity testing. The items for the draft physician questionnaire were taken from the draft patient questionnaire, but formulated from the physician’s viewpoint.

2.7 | Cognitive interviews in patients and physicians

Two trained researchers (NDB, HBR) conducted individual interviews with patients using the draft patient questionnaire and with physicians using the draft physician questionnaire. We determined comprehensibility of the introduction, the items and several response scales, and we assessed if items should be removed, replaced or adapted. We adapted the draft questionnaires between interviews, based on the responses. Finally, we made the decision to align the two questionnaires for sake of comparability and, to that end, selected the same items covering the same domains in the two questionnaires, formulated from the different viewpoints.

3 | RESULTS

3.1 | Sample characteristics

For the formulation of the construct, we approached five international SDM experts to give feedback on our initial selection of domains, of which four responded and two also participated in the in-person meeting. For the feedback on the items, the same five international SDM experts were approached and three of them responded.

In total, 153 patients and 16 physicians participated in this study (Table 1). For content validity testing, 14 patients initially provided informed consent and 12 of them completed the survey. Eleven of the 18 physicians who we approached participated. In total, 185 patients started with the field-test survey, and 133 completed it. Non-completers (N = 52) did not significantly differ from completers regarding age, level of education or gender. Ten patients provided informed consent to participate in the cognitive interviews of whom eight were interviewed. Five of the six physicians who we approached participated in the cognitive interviews.

3.2 | Construct definition and item pool creation

The integration of the findings from the SDM model in oncology and the systematic review resulted in a first selection of 15 domains to define the construct of SDM in oncology (Appendix 1). We clustered the domains by content in six dimensions. We added two domains informed by feedback from the SDM experts. The 17 domains related to both patient and physician behaviours. We then formulated five to 16 items per domain, resulting in a total list of 157 items to start with. Some items were then removed, reformulated or added based on feedback from the SDM experts, resulting in five to 11 items per domain, adding up to 132 items.

3.3 | Content validity testing in patients

We presented the 17 domains with the 132 corresponding items to 12 patients. A number of items that the patients often selected in their top three across domains represented a separate domain, that is ‘The physician offers room for the patient to contribute to SDM’, which was added. Further, it was decided to split the domain ‘The patient considers what is most important to him/her in the context of the treatment options’ into a variant inside versus outside the consultation. Content validity testing in patients thus resulted in the selection of 19 domains and 66 corresponding items. Eleven of the 12 patients considered the introduction to be clear.

3.4 | Content validity testing in physicians and field-testing in patients

Eleven physicians assessed content validity of the 19 domains, and during field-testing 133 patients rated the importance of 66 items considering the 19 domains. The respective selection processes resulted in 14 domains with 23 corresponding items for the draft patient questionnaire, and in 11 domains with 18 corresponding items for the draft physician questionnaire. The 11 domains and corresponding items selected for the physician questionnaire were also part of the patient questionnaire.

3.5 | Cognitive interviews in patients and physicians

Input to the patient and physician cognitive interviews were a draft 24-item patient questionnaire and a draft 18-item physician questionnaire, respectively. The introduction to both the patient and the physician questionnaire explicitly included a statement that the time that the patient and the physician spoke about the treatment options may have entailed one or more conversations. We removed the domain ‘Physician mentions treatment options’ and items that participants considered too much alike. We reworded items that were considered unclear.

The patients indicated that certain questions seemed very similar to each other, although they were asking about different domains. We therefore added a comment to the introduction to the patient questionnaire about the apparent similarity of questions. At the end of the introduction we added a question asking whether the patient considered the introduction to be clear, with the sole aim to stimulate them to actually read the introduction; there is no intent to actually use patients’ response to the item in the definitive questionnaire. Finally, we added a sentence to the introduction to the
patient questionnaire stressing that the questionnaire is not about satisfaction with the physician.

### 3.6 The iSHAREpatient and iSHAREphysician questionnaires

We named the final versions of the questionnaires the iSHAREpatient (Box 2) and the iSHAREphysician (Box 3) questionnaire. They comprise the same construct, consisting of 13 domains, clustered in six dimensions (Box 1). These are assessed using the same 15 items, formulated from the two different viewpoints. Three items explicitly assess patient behaviour. Each item is scored on a six-point scale that ranges from ‘not at all’ (0) to ‘completely’ (5). The questionnaires include two versions of the last item, depending on whether a decision has already been made or not, in order for the questionnaires to be suitable both before and after the final treatment decision has been made.

The weighing of advantages and disadvantages of treatment options during and outside consultations is combined in one item, since patients can do either and do not need to do both. We recommend to assess the time at which patients have weighed treatment options separately, if researchers wish to explore this issue.

We assumed a formative measurement model, and therefore, the most appropriate scores to report on the iSHARE questionnaires are scores per dimension. Dimension scores can be calculated by averaging the scores on the relevant items (range scores, 0-5). It may be

---

**TABLE 1** Characteristics of the participants by study phase

|                              | N or mean (SD) Content validity testing | N or mean (SD) Field-testing | N or mean (SD) Cognitive interviews |
|------------------------------|----------------------------------------|------------------------------|-------------------------------------|
| Cancer patients              | 12                                     | 133                          | 8                                   |
| Sex, female                  | 7                                      | 75                           | 7                                   |
| Age, y                       | 67.8 (8.9)                             | 58.9 (10.8)                  | 63.0 (11.6)                         |
| Primary tumour type<sup>a</sup> |                                |                              |                                      |
| Breast                       | 0                                      | 30                           | 2                                   |
| Urological                   | 4                                      | 25                           | 1                                   |
| Haematological               | 0                                      | 21                           | 0                                   |
| Gastrointestinal             | 0                                      | 20                           | 4                                   |
| Otolaryngology               | 0                                      | 9                            | 0                                   |
| Gynaecological               | 5                                      | 7                            | 0                                   |
| Lung                         | 3                                      | 7                            | 1                                   |
| Skin                         | 0                                      | 5                            | 0                                   |
| Other                        | 0                                      | 9                            | 0                                   |
| Treatment intent             |                                        |                              |                                      |
| Curative                     | 8                                      | 5                            |                                     |
| Palliative                   | 4                                      | 3                            |                                     |
| Education level              |                                        |                              |                                      |
| Low                          | 2                                      | 8                            | 2                                   |
| Intermediate                 | 4                                      | 52                           | 0                                   |
| High                         | 6                                      | 73                           | 6                                   |
| Physicians                   | 11                                     | 5                            |                                     |
| Sex, female                  | 4                                      | 1                            |                                     |
| Age, y                       | 51.9 (7.7)                             | 48.8 (9.1)                   |                                     |
| Years since the start of specialist training | 20.2 (8.2) | 18.8 (8.5)                   |                                     |
| Specialty                    |                                        |                              |                                      |
| Surgery                      | 3                                      | 1                            |                                     |
| Gynaecology                  | 2                                      | 1                            |                                     |
| Pulmonology                  | 2                                      | 0                            |                                     |
| Radiotherapy                 | 2                                      | 1                            |                                     |
| Medical oncology             | 1                                      | 1                            |                                     |
| Urology                      | 1                                      | 1                            |                                     |

<sup>a</sup>Patients participating in the field-testing could indicate more than one cancer diagnosis; 10 patients reported >1 diagnosis.
Box 1 The construct of SDM in oncology; final selection of domains and corresponding items, and clustering of the 13 domains by dimension

Dimension I: Choice awareness
1. The physician establishes (creates or checks) choice awareness—item 8
2. The physician expresses that patient opinion is important in process—item 9
3. The physician provides information on the benefits/risks of the treatment options—item 1, 2 and 6
4. The physician gives information in an objective, balanced, neutral way about each treatment option and its benefit(s) and harm(s)
5. The physician checks patient’s understanding—item 4 and 5
6. The patient asks for clarification—item 7
7. The physician checks patient’s understanding of the treatment options and their risks and benefits
8. The patient asks for clarification, if something about the treatment options is not clear to him/her and/or asks for more information

Dimension II: Medical information
3. The physician provides information on the benefits/risks of the treatment options—item 1, 2 and 6
4. The physician gives information in an objective, balanced, neutral way about each treatment option and its benefit(s) and harm(s)
5. The physician checks patient’s understanding—item 4 and 5
6. The patient asks for clarification—item 7
7. The patient asks for clarification, if something about the treatment options is not clear to him/her and/or asks for more information

Dimension III: Preferences
7. The physician checks own understanding of patient’s values, goals of care, concerns and/or preferences in the context of the treatment options—item 10
8. The patient expresses values, feelings, concerns, thoughts and preferences in the context of the treatment options—item 13
9. The physician supports the patient in deliberation—item 11

Dimension IV: Deliberation
9. The physician supports the patient in deliberation—item 11

Dimension V: Time for deliberation
11. The physician gives the patient room to contribute to SDM—item 12

Dimension VI: Decision
12. Make or explicitly postpone decision that is based on patient’s preferences/values/goals—item 15
13. The physician assesses what the patient needs to make a decision—item 16

If the decision is postponed, the physician more or less explicitly ascertains what the patient needs in order to be able to determine what is important to him/her and/or determine his/her preferred option and/or make the decision, by himself/herself or together with the physician useful to calculate a total score on the questionnaire, which then equals the sum of the scores on the dimensions (range total score, 0-30). Higher scores per dimension and higher total scores indicate higher levels of SDM. A 0-100 total score may be more intuitive, and we therefore recommend a linear transformation of the total score using the following formula: (score/30)*100.

4 | DISCUSSION

In this study, we designed the iSHAREpatient and the iSHAREphysician questionnaires to assess SDM in oncology, based on a thorough development process. The iSHARE questionnaires contain the same items, formulated from the two different viewpoints. Both questionnaires assess patient as well as physician behaviours and aim to assess the SDM process during all consultations relevant to making the decision as well as during time outside of consultations. The iSHARE questionnaires may be used simultaneously or separately in future studies, depending on the research question. We decided that it would be most feasible for future studies if the two questionnaires would contain the smallest possible number of items. Throughout the development process, we therefore constantly prioritized domains...
Box 2  iSHAREpatient†

**iSHARE: Deciding together on the treatment of cancer**

When completing this questionnaire, please think of the last time you spoke to your doctor in the hospital about the treatment options. This may have been in one or multiple conversations. When you are completing the questionnaire, please think about all these conversations.

The statements are about the doctor and about yourself. Some statements may look similar, but ask about something different.

For each statement, tick the answer that fits best. There are no right or wrong answers, it is your opinion that matters. Your answers will remain anonymous, so the doctor will not see them.

This questionnaire is not about how satisfied you are with your doctor. It is about what your doctor said or did during the conversation.

Do you find the information mentioned above clear?

☐ Yes

☐ No. Please state what is not clear to you:.............................................

1. The doctor explained what the advantages of the treatment options are

   not at all          hardly          a little           for a large part
   almost completely  completely

  ☐ ☐ ☐ ☐ ☐ ☐

2. The doctor explained what the disadvantages of the treatment options are

3. The doctor explained the advantages and disadvantages of each treatment option equally well

4. The doctor checked whether I understood the advantages of the treatment options

5. The doctor checked whether I understood the disadvantages of the treatment options

6. The doctor told me how the treatment options differ from each other

7. I asked questions about the treatment options

8. At the beginning of the conversation, the doctor said that there was a choice with regard to my treatment

9. The doctor said that it matters what I think is important

10. The doctor checked whether he/she understood what was important to me

†This is an English translation of the original Dutch iSHAREpatient questionnaire. A translation agency translated the iSHAREpatient using a forward-backward approach.
and items, using the input provided by SDM experts, patients and physicians. Further, SDM measurement instruments from a patient viewpoint often seem to assess satisfaction rather than the extent to which SDM occurred.\textsuperscript{18} We made every effort to clarify to patients that the questionnaire is not about satisfaction, by making this explicit in the introduction of the questionnaire. The iSHARE questionnaires were developed for oncology. Yet, they are not formulated in ways that are specific to oncology and the questionnaires may thus prove useful in other settings as well. Use of the iSHARE questionnaires to assess SDM in non-Dutch cancer settings and/or in other disease settings requires additional content validity testing.

The iSHARE questionnaires have some distinguishing features. First, the total score is not a function of who makes the final decision. This is consistent with our underlying SDM construct and reflects a finding from our earlier qualitative study. Specifically, in SDM in oncology it seems of minor importance who makes the final call, as long as the process was shared.\textsuperscript{11} Such an approach to SDM has been described by others. That is, patients were aware of and benefited from an SDM process, regardless of who they believed made the treatment decision.\textsuperscript{31} Second, the iSHARE questionnaires focus on an SDM process that can extend beyond a consultation. The iSHARE questionnaires therefore can be administered at various time points during the decision-making process.

We started out with the assumption that the assessment of SDM should be based on a formative measurement model, as did the developers of the CollaboRATE\textsuperscript{32} and the OPTION-5.\textsuperscript{12} Assuming a formative measurement model implicates the use of less regular methods to inform item reduction, one of which is rating the importance of items during field-testing.\textsuperscript{1} In our study this method proved a feasible and valuable approach, but it would have been helpful to have specific, evidence-based criteria to apply to the results when narrowing down the item pool. Measuring a construct based on a formative measurement model also implies that the calculation of a total score may not be appropriate, since the dimensions can be independent. Scores are therefore calculated per dimension. Clearly, a total score may sometimes be preferred because it can be a useful summary score. For the present questionnaires, we have no theoretical indication that one or more dimensions should be weighted differently from the others to calculate the total score.\textsuperscript{1,33}

Current measurement instruments assessing SDM from different viewpoints use the same items, formulated from different viewpoints, but agreement has nevertheless been found to be poor. We also used the same items for the iSHARE questionnaires, but let both patients’ and physicians’ views inform the SDM model which we used as input to our SDM construct. Further, both patients and physicians were involved in selecting the domains and items. With these questionnaires, we further ask participants about behaviour, and responses should therefore provide a view on what actually happened during decision-making processes. We therefore expect that the iSHAREpatient and iSHAREphysician questionnaires will show at least a somewhat better agreement than has been found before.\textsuperscript{14,15,19} Nonetheless, interpretation of specific behaviours may still differ between patients and physicians, leading to different views on the extent to which SDM occurred.

We are currently undertaking a validation study to determine whether the iSHAREpatient and iSHAREphysician assess the construct as intended and assess SDM in similar ways from the two different viewpoints. Further assessment of psychometric properties

---

**Box 2** (Continued)

11. The doctor helped me to weigh up the advantages and disadvantages of the treatment options
12. The doctor gave me time to weigh up the advantages and disadvantages of the treatment options (during or after the conversation)
13. I told the doctor what was important to me
14. I weighed up the advantages and disadvantages of the treatment options (before, during or after the conversation)

*Has a decision about treatment been made?*

☐ Yes, the decision has been made → please fill in question 15 below

☐ No, the decision has not been made → please fill in question 16 below

15. The decision takes into account what I consider to be important
16. The doctor has discussed with me what I need in order to weigh up the advantages and disadvantages of the treatment options
Box 3 iSHAREphysician†

iSHARE: Deciding together on the treatment of cancer

When completing this questionnaire, please think about the consultation in which you discussed the decision about the treatment with the patient. You may have had several consultations with the patient about this decision. When you are completing the questionnaire, please think about all these consultations.

The statements are about the patient and about yourself. There are no right or wrong answers.

1. I explained what the advantages of the treatment options are

   not at all      hardly     a little     for a large part
   almost        completely

2. I explained what the disadvantages of the treatment options are

3. I explained the advantages and disadvantages of each treatment option equally well

4. I checked whether the patient understood the advantages of the treatment options

5. I checked whether the patient understood the disadvantages of the treatment options

6. I told the patient how the treatment options differ from each other

7. The patient asked questions about the treatment options

8. At the beginning of the conversation, I said that there was a choice with regard to the patient’s treatment

9. I said that it matters what the patient thinks is important

10. I checked whether I understood what was important to the patient

11. I helped the patient to weigh up the advantages and disadvantages of the treatment options

12. I gave the patient time to weigh up the advantages and disadvantages of the treatment options (during or after the conversation)

13. The patient told me what was important to him/her

14. The patient weighed up the advantages and disadvantages of the treatment options (before, during or after the conversation)

†This is an English translation of the original Dutch iSHAREphysician questionnaire. The translation is based on the translation of the iSHAREpatient.
of the questionnaires is necessary before recommending the use of the iSHARE questionnaires.

4.1 Study limitations

Although we used the original COSMIN checklist as a guideline throughout the development process, our findings should be considered in the light of two main limitations. First, physicians only assessed content validity on domain level and not on item level, for pragmatic reasons. Second, although we aimed to include patients representing a range of different education levels, most included patients were highly educated, resulting in potential biases towards domains and items that may be less important to or less comprehensible for other patients.

5 CONCLUSION

This study provides a patient and a physician questionnaire to assess SDM in oncology, based on a clearly defined construct and a thorough development process. The iSHARE questionnaires are short, assess both patient and physician behaviours, focus on the SDM process during all consultations relevant to making the decision, on the SDM process occurring outside consultations, and may be administered before or after the final decision has been made. Results obtained by using these questionnaires provide starting points to support the SDM process in ways tailored to actual behaviours and to both participants in the process.

ACKNOWLEDGEMENTS

We thank all participating cancer patients and physicians for their time and effort. We thank Prof. Dr Glyn Elwyn, Prof. Dr Martin Härter, Prof. Dr France Légaré and Prof. Dr Richard Street for their contribution to the design of the study, and feedback on the domains and the items, and Martin Härter and Glyn Elwyn for their contribution during the in-person meeting. We thank Bertus Bomhof, MSc, for his contribution to the design of Figure 1.

CONFLICT OF INTEREST

None.

ETHICAL STATEMENT

The Medical Ethical Committee of the Leiden University Medical Center (LUMC) approved the study, which was conducted according to the Dutch Medical Research Involving Human Subjects Act.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Hanna Bomhof-Roordink https://orcid.org/0000-0003-4339-1737
Fania R. Gärtner https://orcid.org/0000-0002-0351-0204
Trudy van der Weijden https://orcid.org/0000-0002-7469-3781
Anne M. Stiggelbout http://orcid.org/0000-0002-6293-4509
Arwen H. Pieterse http://orcid.org/0000-0001-6395-0052

REFERENCES

1. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine—A Practical Guide. New York, USA: Cambridge University Press, New York; 2011.
2. Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366:780-781.
3. Gärtner FR, Bomhof-Roordink H, Smith IP, Scholl I, Stiggelbout AM, Pieterse AH. The quality of instruments to assess the process of shared decision making: a systematic review. PLoS ONE. 2018;13:e0191747.
4. Bouniols N, Leclere B, Moret L. Evaluating the quality of shared decision making during the patient-carer encounter: a systematic review of tools. BMC Res Notes. 2016;9:382.
5. Bomhof-Roodink H, Gärtner FR, Stiggelbout AM, Pieterse AH. Key components of shared decision making models: a systematic review. BMJ Open. 2019;9:e031763.
6. Elwyn G, Edwards A, Wensing M, Hood K, Atwell C, Grol R. Shared decision making: developing the OPTION scale for measuring patient involvement. *Qual Saf Health Care*. 2003;12:93-99.

7. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. *Patient Educ Couns*. 2013;93:102-107.

8. Kriston L, Scholl I, Holzel L, Simon D, Loh A, Harter M. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. *Patient Educ Couns*. 2010;80:94-99.

9. Scholl I, Kriston L, Dirmaier J, Buchholz A, Harter M. Development and psychometric properties of the Shared Decision Making Questionnaire–physician version (SDM-Q-Doc). *Patient Educ Couns*. 2012;88:284-290.

10. Clayman ML, Gulbrandsen P, Morris MA. A patient in the clinic; a person in the world. Why shared decision making needs to center on the person rather than the medical encounter. *Patient Educ Couns*. 2017;100:600-604.

11. Bomhof-Roordink H, Fischer MJ, van Duijn-Bakker N, et al. Shared decision making in oncology: a model based on patients’, health care professionals’, and researchers’ views. *Psychooncology*. 2019;28:139-146.

12. Elwyn G, Tsulukidze M, Edwards A, Legare F, Newcombe R. Using a ‘talk’ model of shared decision making to propose an observation-based measure: observer OPTION 5 Item. *Patient Educ Couns*. 2013;93:265-271.

13. Kasper J, Hoffmann F, Heesen C, Kopke S, Geiger F. MAPPIN’SDM—the multifocal approach to sharing in shared decision making. *PLoS ONE*. 2012;7:e34849.

14. Melbourne E, Roberts S, Durand MA, Newcombe R, Legare F, Elwyn G. Dyadic OPTION: measuring perceptions of shared decision-making in practice. *Patient Educ Couns*. 2011;83:55-57.

15. Kriston L, Harter M, Scholl I. A latent variable framework for modeling dyadic measures in research on shared decision-making. *Z Evid Fortbild Qual Gesundhws*. 2012;106:253-267.

16. Kasper J, Heesen C, Kopke S, Fulcher G, Geiger F. Patients’ and observers’ perceptions of involvement differ. Validation study on inter-relating measures for shared decision making. *PLoS ONE*. 2011;6:e26255.

17. Scholl I, Kriston L, Dirmaier J, Harter M. Comparing the nine-item Shared Decision-Making Questionnaire to the OPTION Scale—an attempt to establish convergent validity. *Health Expect*. 2015;18:137-150.

18. Geessink NH, Ofstad EH, Olde Rikkert MGM, van Goor H, Kasper J, Schoon Y. Shared decision-making in older patients with colorectal or pancreatic cancer: determinants of patients’ and observers’ perceptions. *Patient Educ Couns*. 2018;101:1767-1774.

19. Calderon C, Jiménez-Fonseca P, Ferrando PJ, et al. Psychometric properties of the Shared Decision-Making Questionnaire (SDM-Q-9) in oncology practice. *Int J Clin Health Psychol*. 2018;18:143-151.

20. Jarvis CB, MacKenzie SB, Podsakoff PM. A critical review of construct indicators and measurement model misspecification in marketing and consumer research. *J Consum Res*. 2003;30:199-218.

21. Fayers PM, Hand DJ, Bjordal K, Groenvold M. Causal indicators in quality of life research. *Qual Life Res*. 1997;6:393-406.

22. Wolfschläger D. Short communication: Where is SDM at home? putting theoretical constraints on the way shared decision making is measured. *Z Evid Fortbild Qual Gesundhws*. 2012;106:272-274.

23. Politi MC, Studts JL, Hayslip JW. Shared decision making in oncology practice: what do oncologists need to know? *Oncologist*. 2012;17:91-100.

24. Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. *CA Cancer J Clin*. 2014;64:377-388.

25. Muller-Engelmann M, Keller H, Donner-Banzhoff N, Krones T. Shared decision making in medicine: the influence of situational treatment factors. *Patient Educ Couns*. 2011;82:240-246.

26. Murray E, Charles C, Gafni A. Shared decision-making in primary care: tailoring the Charles et al. model to fit the context of general practice. *Patient Educ Couns*. 2006;62:205-211.

27. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). *Soc Sci Med*. 1997;44:681-692.

28. Terwee CB, Mokkink LB, Knol DL, Ostelo RWJG, Bouter LM, de Vet HCW. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. *Qual Life Res*. 2012;21:651-657.

29. Bomhof-Roordink H, Gärtner FR, Stiggelbout AM, Pieterse AH. *Measuring Shared Decision Making: Choice of Response Scale Matters*. Abstract presented at the International Shared Decision Making Conference, Quebec City, Canada (2019).

30. Rodenburg-Vandenbussche S, Pieterse AH, Kroonenberg PM, et al. Dutch translation and psychometric testing of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in primary and secondary care. *PLoS ONE*. 2015;10:e0132158.

31. Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. *Health Expect*. 2006;9:307-320.

32. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G. The psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. *J Med Internet Res*. 2014;16:e2.

33. Avila ML, Stinson J, Kiss A, Brando LR, Uleryk E, Feldman BM. A critical review of scoring options for clinical measurement tools. *BMC Res Notes*. 2015;8:612.

**How to cite this article:** Bomhof-Roordink H, Gärtner FR, van Duijn-Bakker N, van der Weijden T, Stiggelbout AM, Pieterse AH. Measuring shared decision making in oncology: Development and first testing of the iSHAREpatient and iSHAREphysician questionnaires. *Health Expect*. 2020;23:496–509. [https://doi.org/10.1111/hecx.13015](https://doi.org/10.1111/hecx.13015)
APPENDIX 1
The construct of SDM in oncology; selection of clustered domains during the development process. Clustering is indicated by shading.

| First selection informed by a model of SDM in oncology11 and a review of SDM models2 (§3.2) | Selection after receiving feedback from SDM experts (§3.2) | Selection after content validity testing in cancer patients (§3.3) | Selection after content validity testing in physicians and field-testing in cancer patients (§3.4) | Final selection after cognitive interviews in cancer patients and physicians (§3.6, Box 1) |
|---|---|---|---|---|
| The physician establishes (creates or checks) choice awareness | The physician establishes (creates or checks) choice awareness | The physician establishes (creates or checks) choice awareness | The physician establishes (creates or checks) choice awareness | The physician establishes (creates or checks) choice awareness |
| The physician expresses that patient’s opinion is important in process | The physician expresses that patient’s opinion is important in process | The physician expresses that patient’s opinion is important in process | The physician expresses that patient’s opinion is important in process | The physician expresses that patient’s opinion is important in process |
| The physician invites the patient to share decisions | The physician invites the patient to share decisions | The physician invites the patient to share decisions | The physician invites the patient to share decisions | The physician invites the patient to share decisions |
| The physician decides on the agenda for the consultation | The physician decides on the agenda for the consultation | The physician decides on the agenda for the consultation | The physician decides on the agenda for the consultation | The physician decides on the agenda for the consultation |
| The physician provides information on the benefits/risks of the treatment options | The physician provides information on the benefits/risks of the treatment options | The physician provides information on the benefits/risks of the treatment options | The physician provides information on the benefits/risks of the treatment options | The physician provides information on the benefits/risks of the treatment options |
| The physician informs the patient that more than one option is medically acceptable | The physician informs the patient that more than one option is medically acceptable | The physician informs the patient that more than one option is medically acceptable | The physician informs the patient that more than one option is medically acceptable | The physician informs the patient that more than one option is medically acceptable |
| The physician provides balanced information | The physician provides balanced information | The physician provides balanced information | The physician provides balanced information | The physician provides balanced information |
| The physician checks patient’s understanding | The physician checks patient’s understanding | The physician checks patient’s understanding | The physician checks patient’s understanding | The physician checks patient’s understanding |
| The patient asks about (other) management options | The patient asks about (other) management options | The patient asks about (other) management options | The patient asks about (other) management options | The patient asks about (other) management options |
| The patient asks for clarification | The patient asks for clarification | The patient asks for clarification | The patient asks for clarification | The patient asks for clarification |
| The physician learns about the patient’s values, goals of care, concerns and/or preferences in the context of the treatment options | The physician learns about the patient’s values, goals of care, concerns and/or preferences in the context of the treatment options | The physician learns about the patient’s values, goals of care, concerns and/or preferences in the context of the treatment options | The physician learns about the patient’s values, goals of care, concerns and/or preferences in the context of the treatment options | The physician learns about the patient’s values, goals of care, concerns and/or preferences in the context of the treatment options |
| The patient expresses values, feelings, concerns, thoughts and preferences in the context of the treatment options | The patient expresses values, feelings, concerns, thoughts and preferences in the context of the treatment options | The patient expresses values, feelings, concerns, thoughts and preferences in the context of the treatment options | The patient expresses values, feelings, concerns, thoughts and preferences in the context of the treatment options | The patient expresses values, feelings, concerns, thoughts and preferences in the context of the treatment options |

(Continues)
These domains were not selected for the draft physician questionnaire that was used as input to the cognitive interviews.